Skip to content
User

Seth Klarman

Baupost Group

Seth Klarman FORWARD PHARMA A/S-ADR stake

total: 272

Baupost Group FWPAY trades

Total transactions:
7
New positions:
1
Sold out:
1
Added:
3
Reduced:
2
Held since:
2014 Q4
Held for:
14 quarters
Latest activity:
2018 Q2
According to 2026 Q2 report, Seth Klarman doesn't hold any FORWARD PHARMA A/S-ADR (FWPAY) shares. To date, the estimated cost basis is nearly $41128.11 for "buy" trades and estimated average "sell" price is $5406.72. Baupost Group first purchased FWPAY in 2014 Q4, initially acquiring 2,684 shares. Since the initial investment in FORWARD PHARMA A/S-ADR (FWPAY), Baupost Group has made 6 more transactions.

When did Seth Klarman sell FORWARD PHARMA A/S-ADR (FWPAY)?

Seth Klarman sold off the entire FORWARD PHARMA A/S-ADR (FWPAY) position in 2018 Q2.

When did Seth Klarman buy FORWARD PHARMA A/S-ADR (FWPAY)?

Seth Klarman first invested in FORWARD PHARMA A/S-ADR (FWPAY) in 2014 Q4 at the reported quarter-end price of $41,659.43 per share.

What's the cost basis of Baupost Group's FWPAY stake?

The estimated cost basis for FORWARD PHARMA A/S-ADR (FWPAY) stake is around $41,128.11 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$41,128.11
Weighted AVG sell price:
$5,406.72

Seth Klarman's historical trades in FORWARD PHARMA A/S-ADR

7 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2018 Q2
0.00%
$4,339.83
-100% (-1,424.02)
2018 Q1
0.06%
$4,339.83
-31.87% (-665.98)
2017 Q4
0.15%
$7,359.81
-35.33% (-1,141.68)
2017 Q3
0.49%
$12,139.82
+1.56% (+49.6)
2017 Q2
1.48%
$40,659.25
+14.15% (+394.33)
2017 Q1
1.41%
$43,019.28
+3.88% (+104.06)
2014 Q4
2.20%
$41,659.43
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.